BBIO BridgeBio Pharma

BridgeBio Pharma And Eidos Therapeutics To Present At Upcoming Investor Conferences

BridgeBio Pharma And Eidos Therapeutics To Present At Upcoming Investor Conferences

PALO ALTO, Calif., Feb. 21, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), together with affiliate company Eidos Therapeutics (Nasdaq: EIDX) announced today that they are presenting at two upcoming investor conferences:

  • The SVB Leerink Annual Global Healthcare Conference on Tuesday, February 25, 2020 at 1PM (EST) in New York.
  • The Cowen and Company Annual Health Care Conference on Wednesday, March 4, 2020 at 9:20AM (EST) in Boston.

The presentations will be webcast live and can be accessed at  on the For Investors page under News & Events. The webcast will be available for replay for 30 days.

About BridgeBio Pharma

BridgeBio is a team of experienced drug discoverers, developers and innovators working to create life-altering medicines that target well-characterized genetic diseases at their source. BridgeBio was founded in 2015 to identify and advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. BridgeBio’s pipeline of over 20 development programs includes product candidates ranging from early discovery to late-stage development. For more information, visit .

About Eidos Therapeutics

Eidos is a BridgeBio Pharma affiliate company focused on addressing the large and growing unmet need caused by transthyretin (TTR) amyloidosis (ATTR). Eidos is developing AG10, a potentially disease-modifying therapy for the treatment of ATTR. For more information, please visit

Media contact:

BridgeBio Pharma, Inc.

Grace Rauh



(917) 232-5478

Investor contact:

John Grimaldi, Burns McClellan



212-213-0006 x362

EN
22/02/2020

Underlying

BBIOBridgeBio Pharma

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BridgeBio Pharma

 PRESS RELEASE
Free
BBIO BridgeBio Pharm...

BridgeBio Reports Fourth Quarter and Full Year 2025 Financial Results ...

BridgeBio Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial Updates $154.2 million in total fourth quarter revenues, net, and $502.1 million in full year revenues, net, primarily comprised of net product revenue of $146.0 million and $362.4 million, respectivelyBridgeBio reported three positive Phase 3 trial readouts in just over three months, a demonstration of its unique model for sustainable drug development as described in a recent peer-reviewed manuscriptAttruby continues to demonstrate clinical differentiation as a first-choice therapy in ATTR-CM with the grea...

February 24, 2026 1 EN
 PRESS RELEASE
Free
BBIO BridgeBio Pharm...

BridgeBio to Participate in March Investor Conferences

BridgeBio to Participate in March Investor Conferences PALO ALTO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that members of its management team will participate in the following healthcare investor conferences: TD Cowen 46th Annual Healthcare Conference, Boston, MA: Fireside Chat on Monday, March 2 at 3:50 pm ESTLeerink Partners Global Healthcare Conference, Miami, FL: Fireside Chat on Tuesday, March 10 at 1:00 pm EDTBar...

February 23, 2026 1 EN
 PRESS RELEASE
Free
BBIO BridgeBio Pharm...

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5...

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PALO ALTO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that on February 12, 2026, the compensation committee of BridgeBio’s board of directors approved equity grants to 34 new employees in restricted stock units for an aggregate of 76,701 shares of the Company’s common stock. One-fourth of the shares underlying each employee’s restricted stock u...

February 17, 2026 1 EN
 PRESS RELEASE
Free
BBIO BridgeBio Pharm...

BridgeBio to Report Fourth Quarter and Full Year 2025 Financial Result...

BridgeBio to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 24, 2026 at 4:30 pm ET PALO ALTO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that it will release its fourth quarter and full year 2025 financial results and business updates after the market closes on Tuesday, February 24, 2026. BridgeBio will host a conference call to discuss the financial results and program updates a...

February 17, 2026 1 EN
 PRESS RELEASE
Free
BBIO BridgeBio Pharm...

BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratin...

BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia - PROPEL 3 successfully met the primary endpoint of change from baseline in AHV at Week 52 (p

February 12, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch